The startup has licensed two drugs from Merck KGaA and Blueprint Medicines that can counter both the main genetic drivers of gastrointestinal stromal tumors and mutations that help those tumors evolve drug resistance. The first, called IDRx-42, is already in Phase I clinical testing.

In August 2022, IDRx raised $122 million in Series A funding.